These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29428540)

  • 1. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Pires N; Igreja B; Wright LC; Soares-da-Silva P
    Xenobiotica; 2015; 45(9):828-39. PubMed ID: 25915108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
    Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R; Jadhav G; Vangala S
    Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.
    Bonifácio MJ; Sousa F; Neves M; Palma N; Igreja B; Pires NM; Wright LC; Soares-da-Silva P
    Eur J Pharmacol; 2015 Mar; 751():50-8. PubMed ID: 25641750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
    Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
    Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
    Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
    Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
    Liu H; Huang L; Li Y; Fu T; Sun X; Zhang YY; Gao R; Chen Q; Zhang W; Sahi J; Summerfield S; Dong K
    Drug Metab Dispos; 2017 May; 45(5):449-456. PubMed ID: 28209803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
    Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
    Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.